Unicycive Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-31.41	-18.06	-10.02	-2.26	-2.17
Depreciation & Amortization	0.28	0.16	0.01	0	0
Share-Based Compensation	1.77	1.05	0.97	0.23	0.02
Other Operating Activities	10.21	1.2	3.27	0.57	0.97
Operating Cash Flow	-18.28	-15.65	-5.77	-1.46	-1.18
Capital Expenditures	-0.01	-0	-0.03	0	0
Investing Cash Flow	-0.01	-0	-0.03	0	0
Share Issuance / Repurchase	0	0.01	22.39	0.14	1.17
Debt Issued / Paid	0	0	-0.02	1.42	0
Other Financing Activities	27.54	-0.48	-	-0.12	-
Financing Cash Flow	27.54	-0.47	22.38	1.44	1.17
Net Cash Flow	9.25	-16.12	16.58	-0.02	-0.01
Free Cash Flow	-18.3	-15.65	-5.8	-1.46	-1.18
Free Cash Flow Per Share	-0.75	-1.04	-0.50	-0.17	-0.14

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).